LENZ Therapeutics Inc. (LENZ)
LENZ trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.40
-5.82% on the day
Market cap
$106.8M
Micro cap
Revenue · 2025
$19.1M
Prior year not contiguous
Net income · 2025
-$82.1M
-430.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | LENZ on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001815776 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $19.1M |
| Net income | -$82.1M |
| Operating income | -$91.1M |
| Net margin | -430.3% |
| Operating margin | -477.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $25.2M |
| Total assets | $305.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-04-14 |
| Latest annual report | 10-K | 2026-03-24 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-08-11 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 350 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | $1.63 | -4.12% | $109.2M |
| HUMA | Humacyte Inc. | $0.3589 | -7.88% | $99.7M |
| ARMP | Armata Pharmaceuticals Inc. | $3.10 | -14.60% | $115.3M |
| TNYA | Tenaya Therapeutics Inc. | $0.5210 | -7.87% | $116.8M |
| BDTX | Black Diamond Therapeutics Inc. | $1.68 | -5.08% | $96.5M |
| ATRA | Atara Biotherapeutics Inc. | $9.30 | -0.80% | $93.4M |
| ABOS | Acumen Pharmaceuticals Inc. | $1.81 | -10.15% | $131.3M |
| VYGR | Voyager Therapeutics Inc. | $2.15 | -5.29% | $132.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier